Sereflo is licensed for patients with moderate to severe asthma who are not adequately controlled on a lower strength corticosteroid combination product. It can also be used in patients already adequately controlled on a mid- or high-strength inhaled corticosteroid and a long-acting β2-agonist.
The metered-dose inhaler is available in two strengths:
- 25/125 (salmeterol 25 microgram, fluticasone propionate 125 microgram)
- 25/250 (salmeterol 25 microgram, fluticasone propionate 250 microgram)
Use of a spacer is recommended only for Sereflo 25/250, with which the Volumatic device and the AeroChamber Plus are both compatible. If a spacer is required for use with Sereflo 25/125, prescribers are advised to issue patients with an alternative inhaler.
The efficacy and safety of salmeterol and fluticasone for the treatment of asthma are well established.